Pharmacoeconomic analysis of using Sinemet CR over standard Sinemet in Parkinsonian patients with motor fluctuations

Annals of Pharmacotherapy

Volumn 32, Issue 9, 1998, Pages 878-883

  Hempel, Alan G ^a,b   Wagner, Mary L ^a,c   Maaty, Mohamed A ^b,c   Sage, Jacob I ^d  

^a RUTGERS UNIVERSITY   (United States)

^b Dentistry of New Jersey ^*

^c Rutgers University   (United States)

^d Ross University School of Medicine   (United States)

Author keywords

Carbidopa; Levodopa; Parkinson's disease; Sinemet; Sinemet CR

Indexed keywords

AMANTADINE; BENZATROPINE MESILATE; BROMOCRIPTINE; CARBIDOPA; CARBIDOPA PLUS LEVODOPA; CHOLINERGIC RECEPTOR BLOCKING AGENT; LEVODOPA; PERGOLIDE; SELEGILINE; TRIHEXYPHENIDYL;

ADULT; AGED; ARTICLE; CHOREA; COST EFFECTIVENESS ANALYSIS; DISEASE CONTROL; DRUG COST; DRUG EFFICACY; DRUG FORMULATION; ENZYME INHIBITION; HUMAN; MAJOR CLINICAL STUDY; PARKINSON DISEASE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; TEACHING HOSPITAL;

EID: 0031707114     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.16353     Document Type: Article

References (34)

1. Goetz CG, Tanner CM, Shannon KM, Carroll VS, Klawans HL, Carvey PM, et al. Controlled-release carbidopa/levodopa (CR-4 Sinemet) in Parkinson's disease patients with and without motor fluctuations. Neurology 1988;38:1143-6.
2. Aarli JA, Gilhus NE. Sinemet CR in the treatment of patients with Parkinson's disease already on long-term treatment with levodopa. Neurology 1989;39(suppl 2):82-5.
3. Chase TN, Baronti F, Fabbrini G, Heuser IJ, Juncos JL, Mouradian MM. Rationale for continuous dopaminomimetic therapy in Parkinson's disease. Neurology 1989;39(suppl 2):7-10.
4. Chrisp P, Mammen GJ, Sorkin E. Selegiline - a review of its pharmacology, symptomatic benefits and protective potential in Parkinson's disease. Drugs Aging 1991;1:228-48.
5. Jankovic J, Marsden CD. Therapeutic strategies in Parkinson's disease. In: Jankovic J, Tolosa E, eds. Parkinson's disease and movement disorders. Baltimore: Urban & Schwarzenberg, 1988:95-114.
6. Schelosky L, Poewe W. Current strategies in the drug treatment of advanced Parkinson's disease - new modes of dopamine substitution. Acta Neurol Scand 1993;87(suppl 146):46-9.
7. Drug topics redbook 1993. Oradell, NJ: Medical Economics Co., 1993.
8. Gauthier S, Amyot D. Sustained release antiparkinson agents: controlled release levodopa. Can J Neurol Sci 1992;19:153-5.
9. Sinemet CR for Parkinson's disease. Med Lett 1991;33:92-3.
10. Cedarbaum JM, Hoey M, McDowell F. A double-blind crossover comparison of Sinemet CR4 and standard Sinemet 25/100 in patients with Parkinson's disease and fluctuating motor performance. J Neurol Neurosurg Psychiatry 1989;52:207-12.
11. Rondot P, Ziegler M, Aymard N, Teinturier A. Effect of controlled-release carbidopa/levodopa on motor performance in advanced Parkinson's disease. Neurology 1989;39(suppl 2):74-7.
12. Goetz CG, Tanner CM, Gilley DW, Klawans H. Development and progression of motor fluctuations and side effects in Parkinson's disease. Neurology 1989;39(suppl 2):63-6.
13. Hutton JT, Morris JL, Roman GC, Ink S, Elias J. Treatment of chronic Parkinson's disease with controlled-release carbidopa/levodopa. Arch Neurol 1988;45:861-4.
14. Mark MH, Sage JI. Long-term efficacy of controlled-release carbidopa/ levodopa in patients with advanced Parkinson's disease. Ann Clin Lab Sci 1989;19:415-21.
15. Sage JI, Mark MH. Comparison of controlled-release Sinemet (CR4) and standard Sinemet (25 mg/100 mg) in advanced Parkinson's disease: a double-blind, crossover study. Clin Neuropharmacol 1988;11:174-9.
16. Mark MH, Sage JI. Controlled-release carbidopa-levodopa (Sinemet) in combination with standard Sinemet in advanced Parkinson's disease. Ann Clin Lab Sci 1989;19:101-6.
17. Lang EA. Clinical rating scales and videotape analysis. In: Koller WC, Paulson G, eds. Therapy of Parkinson's disease. 2nd ed. New York: Marcel Dekker, Inc., 1995:21-46.
18. Sage JI, Mark MH. Nighttime levodopa infusions to treat motor fluctuations in advanced Parkinson's disease: preliminary observations. Ann Neurol 1991;30:616-7.
19. Rodnitzky RL, Dickins QS, Dobson J. Long-term clinical efficacy of Sinemet CR in patients with Parkinson's disease. Neurology 1989;39 (suppl 2):92-5.
20. Deleu D, Jacques M, Michotte Y, Ebinger G. Clinical and pharmacokinetic evaluation of controlled-release levodopa/carbidopa (CR-4) in parkinsonian patients with severe motor fluctuations: a six month follow-up study. Clin Neurol Neurosurg 1989;91:303-9.
21. Wolters EC, Horstink MW, Roos RA, Jansen EN. Clinical efficacy of Sinemet CR 50/200 versus Sinemet 25/100 in patients with fluctuating Parkinson's disease. Clin Neurol Neurosurg 1992;94:205-11.
22. Hutton JT, Morris JL, Bush DF, Smith ME, Liss CL, Reines S. Multicenter controlled study of Sinemet CR vs. Sinemet (25/100) in advanced Parkinson's disease. Neurology 1989;39(suppl 2):67-72.
23. Bulling MT, Wing LM, Burns RJ. Controlled release levodopa/carbidopa (Sinemet CR4) in Parkinson's disease - an open evaluation of efficacy and safety. Aust NZJ Med 1991;2:397-9.
24. Friedman JH, Lannon MC. An open trial of controlled release carbidopa/L-dopa (Sinemet CR) for the treatment of mild to moderate Parkinson's disease. Clin Neuropharmacol 1989;12:220-3.
25. LeWitt PA, Nelson MV, Berchow RC, Galloway MP, Kesaree N, Kareti D, et al. Controlled-release carbidopa/levodopa (Sinemet 50/200 CR4): clinical and pharmacokinetic studies. Neurology 1989;39(suppl 2):45-53.
26. Muenster MD, Tyco GM. L-Dopa therapy of Parkinson's disease: plasma L-dopa concentration, therapeutic response, and side effects. Mayo Clin Proc 1971;46:231-9.
27. Ahlskog JE. Treatment of early Parkinson's disease: are complicated strategies justified? Mayo Clin Proc 1996;71:659-70.
28. Parkinson Study Group. Effects of tocopherol and Deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med 1993; 328:176-83.
29. Olanow CW, Hauser RA, Gauger L, Malapira T, Koller W, Hubble J, et al. The effect of Deprenyl and levodopa on the progression of Parkinson's disease. Ann Neurol 1995;38:771-7.
30. Brannan T, Yahr MD. Comparative study of selegiline plus L-dopa-carbidopa versus L-dopa-carbidopa alone in the treatment of Parkinson's disease. Ann Neurol 1995;37:95-8.
31. Parkinson Study Group. Impact of Deprenyl and tocopherol treatment on Parkinson's disease in DATATOP subjects net requiring levodopa. Ann Neurol 1996;39:29-36.
32. Parkinson Study Group. Impact of Deprenyl and tocopherol treatment on Parkinson's disease in DATATOP patients requiring levodopa. Ann Neurol 1996;39:37-45.
33. Ganiants TG, Wong AF. Evaluation of cost-effectiveness research: a survey of recent publications. Fam Med 1991;23:457-61.
34. Jolicoeur LM, Jones-Grizzle AJ, Boyer G. Guidelines for performing a pharmacoeconomic analysis. Am J Hosp Pharm 1992;49:1741-7.